Enzo Biochem Stock (NYSE:ENZ), Trade Ideas

Enzo Biochem

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ASTI

BPTS

DXYZ

GLMD

ICCT

IMRN

INAB

JAGX

MGAM

MRIN

MSFT

PRFX

PSMT

SLNA

VIAO

Shares of  PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter.

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Earnings

QIPT

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

HEICO, EMCOR Group And 3 Stocks To Watch Heading Into Monday

Intraday Update

AKBA

AMNB

APLD

APPH

AURC

BFRG

BLPH

COMP

CRKN

CTCX

TSX:DXF

ELBM

FFIV

GLTO

GNLX

HGEN

HHGC

HOUS

INPX

IPAR

IRBT

KNSA

LOGI

MKFG

NMTC

NMTR

PXMD

RGTI

RMNI

SFWL

SIRI

SPOT

STKH

STOK

TARS

UPST

VTNR

WULF

YELL

YOSH

ZVIA

Gainers


	Aurora Acquisition Corp.  (NASDAQ: AURC) shares jumped 192% to $30.54.


Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem Inc

Enzolytics Inc

iShares MSCI New Zealand ETF

ENZON PHARMS INC by Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals Inc

Enzyme - United States Dollar

ENZYME ENVIRNMNTL SLTNS by Enzyme Environmental Solutions, Inc.

Enzyme Environmental Solutions Inc

Shares of PriceSmart, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psmt#NASDAQ">PSMT</a>) rose sharply in today&rsquo;s pre-market trading as the company posted better-than-expected <a href="https://www.benzinga.com/quote/PSMT/earnings">earnings for its second quarter</a>.
The company reported quarterly earnings of $1.31 per share, beating market estimates of $1.25 per share. PriceSmart&rsquo;s quarterly sales came in at $1.29 billion versus expectations of $1.28 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
PriceSmart shares surged 4.6% to $86.90 in pre-market trading.
<h3>Here are some other stocks moving in pre-market trading. 
Gainers</h3>
<ul>
<li>Marin Software Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrin#NASDAQ">MRIN</a>) shares rose 76.1% to $0.5054 in pre-market trading after the company announced upgrades to its Microsoft Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) advertising integration.</li>
<li>iCoreConnect Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icct#NASDAQ">ICCT</a>) shares rose 46.4% to $1.64 in pre-market trading. iCoreConnect, last month, closed $2,375,000 convertible note financing.</li>
<li>Nano Labs Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/na#NASDAQ">NA</a>) gained 35.1% to $2.00 in pre-market trading. Nano Labs recently filed annual report on Form 20-F for fiscal year 2023.</li>
<li>IN8bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inab#NASDAQ">INAB</a>) shares gained 20.2% to $1.31 in pre-market trading after the company announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell platform.</li>
<li>Jaguar Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jagx#NASDAQ">JAGX</a>) gained 18.8% to $0.1069 in pre-market trading after the company reported approval for all proposals at its special meeting of stockholders.</li>
<li>Immuron Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrn#NASDAQ">IMRN</a>) climbed 16.2% to $3.20 in pre-market trading after the company disclosed record sales (unaudited) of Travelan&reg;.</li>
<li>Desktop Metal, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dm#NYSE">DM</a>) shares gained 12.5% to $1.17 in pre-market trading after declining around 4% on Tuesday.</li>
<li>Yatsen Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ysg#NYSE">YSG</a>) rose 11.2% to $3.48 in pre-market trading.</li>
<li>Galmed Pharmaceuticals Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glmd#NASDAQ">GLMD</a>) gained 10.3% to $0.43 in pre-market trading.</li>
</ul>
&nbsp;
<h3>Losers</h3>
&nbsp;
<ul>
<li>Ascent Solar Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asti#NASDAQ">ASTI</a>) declined 50% to $0.1374&nbsp;in pre-market trading after the company announced pricing of a $6 million public offering of shares at $0.14 per share.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) fell 25.8% to $47.50 in pre-market trading after dipping over 35% on Tuesday.</li>
<li>PainReform Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prfx#NASDAQ">PRFX</a>) fell 23.2% to $1.16 in pre-market trading after declining 11% on Tuesday. PainReform recently announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to topical post-surgical pain management products available in the market.</li>
<li>Velo3D, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vld#NYSE">VLD</a>) fell 22.4% to $0.3601 in pre-market trading after announcing a proposed public offering.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) shares declined 21.4% to $0.0617 in pre-market trading after jumping over 96% on Tuesday.</li>
<li>Mobile Global Esports Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgam#NASDAQ">MGAM</a>) fell 19.1% to $0.1748 pre-market trading after surging around 78% on Tuesday.</li>
<li>VIA optronics AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/viao#NYSE">VIAO</a>) shares fell 18.8% to $0.7298 in pre-market trading. VIA optronics announced intention to voluntarily delist its ADSs from the New York Stock Exchange.</li>
<li>Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) fell 10.6% to $0.3522 in pre-market trading. Biophytis shares jumped around 32% on Tuesday after the company reported a year-over-year increase in FY23 EPS results.</li>
<li>Enzo Biochem, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enz#NYSE">ENZ</a>) shares fell 7.5% to $1.11 in pre-market trading. Eco Wave.</li>
<li>SMART Global Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgh#NASDAQ">SGH</a>) fell 7.4% to $24.00 pre-market trading. Smart Global posted better-than-expected results for its second quarter. The company saw third-quarter earnings of 30 cents per share, plus or minus 15 cents, versus the 28 cent estimate. The company expects third-quarter revenue of $300 million, plus or minus $25 million, versus the $307.864 million estimate.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38176264/delta-air-lines-pricesmart-and-3-stocks-to-watch-heading-into-wednesday"> Delta Air Lines, PriceSmart And 3 Stocks To Watch Heading Into Wednesday</a>

Enzo Biochem Q2 EPS $(0.06) Up From $(0.23) YoY, Sales $8.55M

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects HEICO Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hei#NYSE">HEI</a>) to report quarterly earnings at 68 cents per share on revenue of $898.25 million after the closing bell. HEICO shares fell 0.6% to $181.85 in after-hours trading.</li>
<li>EMCOR Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eme#NYSE">EME</a>) said Mark A. Pompa, Executive Vice President and Chief Financial Officer, and R. Kevin Matz, Executive Vice President Shared Services, will step down from their respective positions, effective April 1, 2024. The company named Jason R. Nalbandian as Senior Vice President and CFO. EMCOR shares fell 0.9% to $216.64 in the after-hours trading session.</li>
<li>Analysts expect GEE Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/job#NYSE">JOB</a>) to earn 2 cents per share on revenue of $40.36 million for the latest quarter. The company will release earnings after the markets close. GEE Group shares gained 2.4% to $0.5470 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<ul>
<li>Enzo Biochem, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enz#NYSE">ENZ</a>) posted a loss of 13 cents per share for the first quarter versus a year-ago loss of 22 cents per share. Enzo Biochem shares gained 4.5% to $1.39 in the after-hours trading session.</li>
<li>Quipt Home Medical Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qipt#NASDAQ">QIPT</a>) is expected to announce its fourth-quarter financial results on Dec. 18, 2023. Quipt Home Medical shares gained 4.6% to $4.54 in the after-hours trading session.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36256926/2u-and-3-other-stocks-under-4-insiders-are-buying"> 2U And 3 Other Stocks Under $4 Insiders Are Buying </a>

Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) reported quarterly losses of $(0.13) per share. This is a 40.91 percent increase over losses of $(0.22) per share from the same period last year.

Enzo Biochem Q1 EPS $(0.13) Up From $(0.22) YoY

<h3>Gainers</h3>
<ul>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares increased by 36.2% to $2.22 during Tuesday's pre-market session. The company's market cap stands at $6.9 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares increased by 30.02% to $0.23. The market value of their outstanding shares is at $7.0 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares increased by 28.4% to $1.22. The market value of their outstanding shares is at $17.9 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares increased by 22.03% to $0.22. The company's market cap stands at $10.7 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares moved upwards by 19.23% to $0.62. The company's market cap stands at $5.8 million. </li>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) stock increased by 17.47% to $2.42. The market value of their outstanding shares is at $133.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) shares fell 24.1% to $4.45 during Tuesday's pre-market session. The market value of their outstanding shares is at $608.2 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares declined by 13.67% to $1.2. The market value of their outstanding shares is at $7.7 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock fell 13.39% to $1.1. The market value of their outstanding shares is at $55.5 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares decreased by 12.22% to $1.94. The company's market cap stands at $36.3 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 11.91% to $0.41. The company's market cap stands at $6.2 million. </li>
<li>Nemaura Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRD#NASDAQ">NMRD</a>) stock fell 10.17% to $0.21. The market value of their outstanding shares is at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALZN

BCLI

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CNTB

FRES

Morgan Stanley Capital Protected Notes for S&P 500 Index

NMRD

SILO

STSS

TCBP

TCON

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

&nbsp;Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective&nbsp;September 5, 2023, with Enzo&#39;s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO.
&quot;We thank Hamid for the commitment he has brought to Enzo Biochem, Inc.&quot;&nbsp; Chairperson of the Board Mary Tagliaferri, MD stated, &quot;Hamid successfully led the Company through the divestiture of Enzo Clinical Lab, Inc.&nbsp; We wish him well in all his future endeavors and are excited to focus on the life sciences division. We are confident in Kara to lead the Company forward during this transition.&nbsp; Kara is a seasoned healthcare executive with over thirty years of experience in strategic and tactical marketing, sales, manufacturing and general operations management, including thirteen years of experience at Enzo.&quot;
&quot;It has been an honor to serve the employees, shareholders and Board of Directors of the company and I firmly believe Enzo has a bright future,&quot; said Mr. Erfanian.
Ms. Cannon stated, &quot;I am appreciative to the Board of Directors for the opportunity to unlock the full potential of Enzo Life Sciences through the expansion of our product line and growth in sales. I look forward to leading the company during this exciting next phase of development.&quot;

Management

Enzo Biochem Announces Departure Of Hamid Erfanian And Appointment Of Kara Cannon As Interim CEO, Effective September 5, 2023

<h3>Gainers</h3>
<ul>
<li>Aurora Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aurc#NASDAQ">AURC</a>) shares jumped 192% to $30.54.</li>
<li>Inpixon (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inpx#NASDAQ">INPX</a>) gained 117% to $0.33 after the company agreed to merge with XTI Aircraft Company.</li>
<li>Electra Battery Materials Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elbm#NASDAQ">ELBM</a>) shares shot up 71.5% to $2.11 after jumping 22% on Monday. Electra Battery Materials said its battery grade cobalt supply agreement with LG Energy Solution has been extended and expanded from terms initially announced in Sept. 2022.</li>
<li>Bullfrog AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfrg#NASDAQ">BFRG</a>) shares gained 35.3% to $4.68 after the company announced US patent for novel prodrugs of mebendazole and their use in treating cancer.</li>
<li>Kiniksa Pharmaceuticals, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/knsa#NASDAQ">KNSA</a>) climbed 31.7% to $19.68 following strong quarterly results.</li>
<li>Yoshiharu Global Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yosh#NASDAQ">YOSH</a>) shares gained 31.5% to $0.8425.</li>
<li>Steakholder Foods Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stkh#NASDAQ">STKH</a>) surged 29.4% to $1.3199. Steakholder Foods recently announced it signed its first multimillion dollar agreement with an accredited GCC governmental body to commercialize its 3D bio-printing technology.</li>
<li>Galecto, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glto#NASDAQ">GLTO</a>) gained 27.2% to $2.95.</li>
<li>HHG Capital Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hhgc#NASDAQ">HHGC</a>) jumped 22.5% to $13.00.</li>
<li>Markforged Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mkfg#NASDAQ">MKFG</a>) jumped 21.7% to $1.9594.</li>
<li>American National Bankshares Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amnb#NASDAQ">AMNB</a>) gained 20.3% to $38.00 after reporting second-quarter results.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akba#NASDAQ">AKBA</a>) rose 19.7% to $1.46.</li>
<li>Rigetti Computing, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgti#NASDAQ">RGTI</a>) climbed 19.7% to $2.06.</li>
<li>Upstart Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upst#NASDAQ">UPST</a>) gained 19.5% to $64.19. BTIG maintained Upstart with a Buy and raised the price target from $42 to $72.</li>
<li>Applied Digital Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apld#NASDAQ">APLD</a>) gained 18.5% to $10.40. Needham maintained Applied Digital with a Buy and raised the price target from $16 to $17.5.</li>
<li>Genelux Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnlx#NASDAQ">GNLX</a>) rose 18.4% to $23.99.</li>
<li>Shengfeng Development Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfwl#NASDAQ">SFWL</a>) gained 17.2% to $6.09.</li>
<li>Dunxin Financial Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxf#NYSE">DXF</a>) climbed 16.8% to $1.73.</li>
<li>Pagaya Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgy#NASDAQ">PGY</a>) rose 15.7% to $2.2215.</li>
<li>Carmell Therapeutics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctcx#NASDAQ">CTCX</a>) rose 15.4% to $4.0150 after falling over 36% on Monday.</li>
<li>Logitech International S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/logi#NASDAQ">LOGI</a>) rose 13.4% to $71.39 following strong quarterly results.</li>
<li>TeraWulf Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wulf#NASDAQ">WULF</a>) gained 12.3% to $3.83.</li>
<li>POSCO Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pkx#NYSE">PKX</a>) rose 12% to $132.38 after Chinese leaders indicated support for stimulus measures. Economic stimulus measures in China could lift demand for metals and materials.</li>
<li>Packaging Corporation of America (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pkg#NYSE">PKG</a>) surged 10.3% to $153.00. The company late Monday reported mixed Q2 results.</li>
<li>Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) gained 9.2% to $2.01 after falling over 17% on Monday.</li>
<li>Hudbay Minerals Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hbm#NYSE">HBM</a>) rose 9.2% to $5.76 after Barclays upgraded the stock from Equal-Weight to Overweight.</li>
<li>Enzo Biochem, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enz#NYSE">ENZ</a>) shares gained 8.8% to $1.48. Enzo Biochem closed a transaction to sell certain assets of Enzo&rsquo;s Clinical laboratory division to Laboratory Corporation of America Holdings.</li>
<li>Inter Parfums, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipar#NASDAQ">IPAR</a>) gained 8.5% to $142.09 after the company reported better-than-expected second-quarter revenue results and raised FY23 revenue guidance.</li>
<li>Anywhere Real Estate Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hous#NYSE">HOUS</a>) surged 8.3% to $8.31 following quarterly results.</li>
<li>AppHarvest, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apph#NASDAQ">APPH</a>) gained 8% to $0.0973. AppHarvest shares declined 73% on Monday after the company announced Chapter 11 filing to support a financial and operational transition.</li>
<li>Compass, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/comp#NYSE">COMP</a>) rose 7.4% to $4.2750.</li>
<li>Cleveland-Cliffs Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clf#NYSE">CLF</a>) gained 7.4% to $17.74 after the company reported better-than-expected second-quarter revenue results.</li>
<li>Xerox Holdings Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xrx#NYSE">XRX</a>) climbed 7% to $16.58 after mixed second-quarter results and FY23 guidance boost.</li>
<li>Alcoa Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aa#NYSE">AA</a>) gained 6.4% to $35.92. Alcoa named Renato Bacchi as Executive Vice President and Chief Commercial Officer, effective Aug. 1, 2023</li>
<li>F5, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ffiv#NASDAQ">FFIV</a>) gained 5.7% to $158.73 as the company reported better-than-expected earnings for its third quarter.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Humanigen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hgen#NASDAQ">HGEN</a>) shares fell 75.1% to $0.0476. Humanigen said it anticipates that it will not be able to continue as a going concern and is exploring all restructuring options, including bankruptcy.</li>
<li>Bellerophon Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blph#NASDAQ">BLPH</a>) fell 38% to $0.4387 after the company received a delisting notice.</li>
<li>Stoke Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stok#NASDAQ">STOK</a>) fell 33% to $6.39 after the company announced new safety and efficacy data from STK-001 in the two ongoing Phase 1/2a studies and the SWALLOWTAIL open-label extension study in children and adolescents with Dravet syndrome.</li>
<li>NeuroOne Medical Technologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmtc#NASDAQ">NMTC</a>) fell 32% to $1.08. NeuroOne Medical priced the underwritten registered public offering of 5.25 million shares at $1.00 per share.</li>
<li>Rimini Street, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmni#NASDAQ">RMNI</a>) fell 29.4% to $3.40. Rimini Street issued a statement on U.S. Federal Court Ruling.</li>
<li>Tarsus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tars#NASDAQ">TARS</a>) fell 23.9% to $18.25. The FDA has approved Tarsus Pharmaceuticals&#39; Xdemvy (Lotilaner Ophthalmic Solution, formerly TP-03) 0.25% For Demodex Blepharitisf</li>
<li>9 Meters Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmtr#NASDAQ">NMTR</a>) declined 23.4% to $0.0970.</li>
<li>Zevia PBC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvia#NASDAQ">ZVIA</a>) dipped 23.3% to $3.2450 after announcing preliminary net sales for the second quarter.</li>
<li>Yellow Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yell#NASDAQ">YELL</a>) fell 22% to $1.0550.</li>
<li>Vertex Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtnr#NASDAQ">VTNR</a>) fell 21.1% to $5.18.</li>
<li>TrueBlue, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tbi#NYSE">TBI</a>) tumbled 17.8% to $15.02 after the company reported worse-than-expected second-quarter financial results.</li>
<li>PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) fell 15% to $0.7311. PaxMedica shares gained 7% on Monday after the released topline results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness study.</li>
<li>Spotify Technology S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spot#NYSE">SPOT</a>) declined 14.3% to $140.34 after the company reported second-quarter earnings.</li>
<li>Sirius XM Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/siri#NASDAQ">SIRI</a>) fell 13.3% to $5.20.</li>
<li>iRobot Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irbt#NASDAQ">IRBT</a>) dipped 12.7% to $40.95 after Amazon reduced the takeover price by 15% for debt adjustments.</li>
<li>RTX Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rtx#NYSE">RTX</a>) fell 12.7% to $84.61. The company in its earnings report disclosed that Pratt &amp; Whitney has determined that a rare condition in powder metal used to manufacture certain engine parts will require accelerated fleet inspection.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) declined 11.5% to $5.18 as the stock sees volatility after a court recently rejected the company&#39;s proposed plan to convert preferred shares to common units and implement a stock split.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyt#NASDAQ">LYT</a>) shares fell 10.8% to $0.41.</li>
<li>Alaska Air Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alk#NYSE">ALK</a>) fell 9.3% to $48.38 after the company reported second-quarter financial results and issued guidance for third quarter and FY23.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crkn#NASDAQ">CRKN</a>) fell 9.2% to $0.0724 after declining 5% on Monday.</li>
<li>Mueller Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mli#NYSE">MLI</a>) declined 8.6% to $83.86 after the company reported worse-than-expected second-quarter revenue results.</li>
<li>Lamb Weston Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lw#NYSE">LW</a>) fell 8.5% to $103.09 following fourth-quarter earnings.</li>
<li>Sensata Technologies Holding plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/st#NYSE">ST</a>) declined 7.6% to $42.94 after the company reported second-quarter financial results and issued third-quarter guidance below estimates.</li>
<li>Spark Networks SE (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lov#NASDAQ">LOV</a>) fell 6.5% to $0.2590 after jumping 21% on Monday.</li>
<li>Rackspace Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxt#NASDAQ">RXT</a>) shares fell 5.8% to $2.42. Citigroup downgraded Rackspace Tech from Neutral to Sell and raised the price target from $1.25 to $1.5.</li>
<li>The Goodyear Tire &amp; Rubber Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gt#NASDAQ">GT</a>) declined 4.3% to $15.24.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/07/33369580/bitcoin-edges-lower-compound-becomes-top-loser"> Bitcoin Edges Lower; Compound Becomes Top Loser</a>

Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) stock moved upwards by 45.4% to $5.03 during Tuesday's pre-market session. The company's market cap stands at $30.6 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) shares rose 16.91% to $1.59. The market value of their outstanding shares is at $79.0 million. </li>
<li>Aravive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAV#NASDAQ">ARAV</a>) shares moved upwards by 14.09% to $1.7. The market value of their outstanding shares is at $101.7 million. </li>
<li>Novan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOVN#NASDAQ">NOVN</a>) stock increased by 11.5% to $0.14. The market value of their outstanding shares is at $3.9 million. </li>
<li>Biotricity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCY#NASDAQ">BTCY</a>) stock rose 10.72% to $3.51. The market value of their outstanding shares is at $30.7 million. </li>
<li>Alpha Tau Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRTS#NASDAQ">DRTS</a>) stock moved upwards by 9.97% to $4.41. The market value of their outstanding shares is at $305.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Humanigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGEN#NASDAQ">HGEN</a>) shares decreased by 70.6% to $0.06 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.6 million. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares declined by 38.35% to $0.98. The company's market cap stands at $17.2 million. </li>
<li>Bellerophon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLPH#NASDAQ">BLPH</a>) stock fell 34.27% to $0.47. The market value of their outstanding shares is at $4.8 million. </li>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) stock declined by 29.18% to $6.75. The company's market cap stands at $298.2 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock decreased by 16.13% to $2.15. The company's market cap stands at $17.5 million. </li>
<li>ViewRay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAY#NASDAQ">VRAY</a>) shares fell 12.5% to $0.04. The company's market cap stands at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARAV

BNOX

BTCY

DRTS

NOVN

VRAY

<h3>Gainers</h3>
<ul>
<li>Electra Battery Materials Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elbm#NASDAQ">ELBM</a>) shares surged 59% to $1.96 in pre-market trading after jumping 22% on Monday. Electra Battery Materials said its battery grade cobalt supply agreement with LG Energy Solution has been extended and expanded from terms initially announced in Sept. 2022.</li>
<li>Carmell Therapeutics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctcx#NASDAQ">CTCX</a>) rose 52% to $5.30 in pre-market trading after falling over 36% on Monday.</li>
<li>Yoshiharu Global Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yosh#NASDAQ">YOSH</a>) shares gained 50.5% to $0.9620 in pre-market trading.</li>
<li>AppHarvest, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apph#NASDAQ">APPH</a>) gained 25% to $0.1128 in pre-market trading. AppHarvest shares declined 73% on Monday after the company announced Chapter 11 filing to support a financial and operational transition.</li>
<li>Enzo Biochem, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enz#NYSE">ENZ</a>) shares gained 22.1% to $1.66 in pre-market trading. Enzo Biochem closed a transaction to sell certain assets of Enzo&rsquo;s Clinical laboratory division to Laboratory Corporation of America Holdings.</li>
<li>Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) gained 13.1% to $2.08 in pre-market trading after falling over 17% on Monday.</li>
<li>Expion360 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xpon#NASDAQ">XPON</a>) shares climbed 12.6% to $5.60 in pre-market trading. Expion360 expanded its sales and distribution partnership with Meyer Distributing, a leading national marketer and distributor of automotive and RV specialty products.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) shares rose 11.8% to $2.85 in pre-market trading. Agrify recently reported a 1-for-20 reverse stock split.</li>
<li>FaZe Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faze#NASDAQ">FAZE</a>) rose 11.7% to $0.4580 in pre-market trading after gaining over 5% on Monday. New reports suggested the company is evaluating a pair of acquisition offers.</li>
<li>Aravive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arav#NASDAQ">ARAV</a>) shares rose 11.4% to $1.66 in pre-market trading after falling 10% on Monday.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bellerophon Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blph#NASDAQ">BLPH</a>) fell 47.7% to $0.3701 in pre-market trading.</li>
<li>NeuroOne Medical Technologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmtc#NASDAQ">NMTC</a>) fell 27% to $1.16 in pre-market trading after the company reported a proposed public offering of common stock.</li>
<li>Spark Networks SE (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lov#NASDAQ">LOV</a>) fell 20.6% to $0.22 in pre-market trading after jumping 21% on Monday.</li>
<li>ABVC BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abvc#NASDAQ">ABVC</a>) shares fell 14.6% to $3.33 in pre-market trading after the company announced 1-for-10 reverse stock split.</li>
<li>ETAO International Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etao#NASDAQ">ETAO</a>) fell 14.4% to $0.4271 in pre-market trading after gaining 10% on Monday.</li>
<li>Aurora Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aurc#NASDAQ">AURC</a>) fell 8.8% to $11.29 in pre-market trading.</li>
<li>Knightscope, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kscp#NASDAQ">KSCP</a>) shares fell 8.5% to $1.48 in pre-market trading. Knightscope shares gained 35% on Monday after the company announced it received a letter of compliance from the Nasdaq.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crkn#NASDAQ">CRKN</a>) fell 8.2% to $0.0731 in pre-market trading after declining 5% on Monday.</li>
<li>PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) fell 8.1% to $0.79 in pre-market. PaxMedica shares gained 7% on Monday after the released topline results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness study.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyt#NASDAQ">LYT</a>) shares fell 6.8% to $0.4290 in pre-market trading.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/07/33361238/microsoft-likely-to-report-higher-quarterly-earnings-heres-a-look-at-recent-price-target-changes-by"> Microsoft Likely To Report Higher Quarterly Earnings; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>

ABVC

AGFY

ETAO

FAZE

KSCP

XPON

Why Expion360 Holdings Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock moved upwards by 12.5% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $76.0 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares rose 10.1% to $0.86. The company's market cap stands at $9.1 million. </li>
<li>NextGen Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGN#NASDAQ">NXGN</a>) shares increased by 8.89% to $18.0. The market value of their outstanding shares is at $1.1 billion. The company's, Q1 earnings came out today. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock rose 6.87% to $1.4. The market value of their outstanding shares is at $12.6 million. </li>
<li>Ra Medical Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RMED#AMEX">RMED</a>) shares rose 6.56% to $0.72. The company's market cap stands at $4.6 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock increased by 6.13% to $2.25. The market value of their outstanding shares is at $5.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) stock fell 27.1% to $1.16 during Monday's after-market session. Trading volume for this security closed at 163.1K, accounting for 102.5% of its average full-day volume over the last 100 days. The company's market cap stands at $20.3 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) stock declined by 8.89% to $225.0. The company's market cap stands at $6.8 billion. As per the news, the Q2 earnings report came out today. </li>
<li>Etao International Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETAO#NASDAQ">ETAO</a>) shares fell 7.9% to $0.46. Etao International Co's trading volume hit 101.4K shares by close, accounting for 19.4% of its average volume over the last 100 days. The market value of their outstanding shares is at $47.0 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 6.21% to $6.05. The market value of their outstanding shares is at $1.4 million. </li>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) stock fell 6.05% to $0.28. The market value of their outstanding shares is at $7.3 million. </li>
<li>Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) shares declined by 5.1% to $1.49. The company's market cap stands at $53.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARMP

AVGR

BDRX

ISPC

MEDP

NEXI

NXGN

PSTV

RMED

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 114.8% to $0.43 during Tuesday's regular session. The current volume of 86.1 million shares is 45600.6% of Adial Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $13.0 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock increased by 104.38% to $7.13. As of 13:37 EST, this security is trading at a volume of 19.9 million shares, making up 10723.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $82.2 million. </li>
<li>Eloxx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELOX#NASDAQ">ELOX</a>) stock rose 104.34% to $7.99. The current volume of 36.4 million shares is 8214.4% of Eloxx Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:37 EST). The company's market cap stands at $17.3 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares moved upwards by 59.19% to $6.75. As of 13:37 EST, this security is trading at a volume of 2.5 million shares, making up 2913.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.5 million. </li>
<li>Freeline Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRLN#NASDAQ">FRLN</a>) stock moved upwards by 40.37% to $3.86. Freeline Therapeutics's stock is trading at a volume of 1.0 million shares as of 13:37 EST. This is 858.5% of its average full-day volume over the last 100 days. The company's market cap stands at $16.7 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) shares increased by 26.95% to $1.79. As of 13:37 EST, Nanoviricides's stock is trading at a volume of 2.2 million, which is 4135.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock declined by 25.7% to $2.11 during Tuesday's regular session. Journey Medical's stock is trading at a volume of 1.1 million shares as of 13:37 EST. This is 952.9% of its average full-day volume over the last 100 days. The company's market cap stands at $38.2 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares declined by 16.24% to $2.6. The company's market cap stands at $20.4 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock decreased by 14.89% to $3.03. As of 13:37 EST, this security is trading at a volume of 151.0K shares, making up 351.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $11.7 million. </li>
<li>Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) shares declined by 14.77% to $20.9. Trading volume for Viridian Therapeutics's stock is 3.4 million as of 13:37 EST. This is 517.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $901.4 million. </li>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) stock fell 11.61% to $3.96. Sientra's stock is trading at a volume of 1.1 million shares as of 13:37 EST. This is 99.0% of its average full-day volume over the last 100 days. The company's market cap stands at $44.3 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) shares declined by 10.44% to $1.63. As of 13:37 EST, Enzo Biochem's stock is trading at a volume of 416.8K, which is 276.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $81.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

BRTX

DERM

ELOX

FRLN

GDTC

NNVC

NTRB

SIEN

VRDN

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock moved upwards by 153.9% to $8.86 during Tuesday's pre-market session. The market value of their outstanding shares is at $102.1 million. </li>
<li>Better Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTTX#NASDAQ">BTTX</a>) stock rose 35.55% to $1.22. The market value of their outstanding shares is at $38.7 million. </li>
<li>Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) stock rose 28.64% to $1.19. The market value of their outstanding shares is at $13.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares moved upwards by 25.3% to $0.56. The company's market cap stands at $2.6 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock rose 18.63% to $0.24. The company's market cap stands at $7.1 million. </li>
<li>Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) stock rose 13.88% to $5.65. The market value of their outstanding shares is at $231.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) stock decreased by 17.1% to $20.33 during Tuesday's pre-market session. The company's market cap stands at $876.8 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares declined by 14.33% to $3.05. The company's market cap stands at $11.8 million. </li>
<li>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) shares decreased by 12.06% to $7.73. The company's market cap stands at $1.7 billion. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock fell 9.9% to $1.64. The market value of their outstanding shares is at $81.5 million. </li>
<li>Enochian BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENOB#NASDAQ">ENOB</a>) shares decreased by 8.69% to $0.47. The market value of their outstanding shares is at $30.1 million. </li>
<li>Histogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTO#NASDAQ">HSTO</a>) shares fell 7.77% to $0.81. The market value of their outstanding shares is at $3.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABOS

BTTX

CING

ENOB

HSTO

IOVA

Enzo Biochem Said On July, 3 Unit Entered Amendment To Purchase Agreement Dated March 16, 2023;  Amendment Adjusted Purchase Price For Business From $146M To $113.25M

On Wednesday, shares of Enzo Biochem Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enz#NYSE">ENZ</a>) experienced volatile short activity. After the activity, the stock price went up +1.03% to $1.96.
The overall sentiment for ENZ has been Bullish.
The signal from the volatility alert is trending Bullish. Therefore, the recommendation is to Strong Buy.
The volatility alert was produced on the prior trading date, 6/21/2023 with a volatility change of +78.77%. The current volatility indicator stands at 12.849.
Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the purpose of providing liquidity to short sellers. When unusual activity occurs in the securities lending markets, it acts as an upstream indicator to what is likely to occur downstream in the regular stock market.
Understanding the Volatility Alert: Overall sentiment is considered &quot;bear&quot; when broad market activity of the stock has been shown to indicate a negative directional basis, or is considered &quot;bull&quot; when indicating a positive directional basis. The securities lending volatility indicator provides a signal when it detects unusual short activity. Unusual short activity is based off a computer generated algorithmic formula utilizing securities lending trade details such as the volume of shares being shorted, the rate being paid to short the shares, and the type of collateral being posted - amongst other variables. The current volatility is the respective trading day&#39;s calculated securities lending volatility value. The volatility percentage change is the percentage difference in volatility between the two most recent days. The recommendation is a suggestive strategy, inferred from the strength of the Signal Trending, Current Volatility, and Volatility % Change. Recommendations may include, &quot;Strong Buy&quot;, &quot;Strong Sell&quot;, &quot;Increase Short Exposure&quot;, &quot;Decrease Short Exposure&quot;, or &quot;Market Neutral&quot;.
ANY INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR IMPLY INVESTMENT ADVICE

Biotech

Short Ideas

General

Short Volatility Alert: Enzo Biochem Inc

Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) reported quarterly losses of $(0.31) per share. This is a 210 percent decrease over losses of $(0.10) per share from the same period last year. The company reported $16.11 million in sales this quarter. This is a 38.57 percent decrease over sales of $26.22 million the same period last year.

Enzo Biochem Q3 EPS $(0.31) Down From $(0.10) YoY, Sales $16.11M Down From $26.22M YoY

The Company is in the process of evaluating the full scope of the costs and related impacts of this incident.

Enzo Biochem Expects Certain Expenses Related To Ransomware Attack, Including Expenses To Respond To, Remediate And Investigate This Matter

Enzo Biochem Says Social Security Numbers Of Approximately 600,000 Individuals May Also Have Been Involved From Previously Reported Ransomware Attack

As previously disclosed, on April 6, 2023, Enzo Biochem&nbsp;experienced a ransomware attack that impacted certain information technology systems.

Enzo Biochem Says Identified Unauthorized Access To Or Acquisition Of Clinical Test Information Of Approximately 2.47M Individuals

Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>), announced today that &nbsp;the preliminary voting results from the Inspector of Election at today's Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo's outstanding common stock. Pending final results of the vote, Enzo will have obtained shareholder approval and met all regulatory requirements for closing the sale of substantially all of the operating assets and assignment of certain liabilities of Enzo's Clinical Labs division.
"We are grateful for the continuous support from our shareholders, many of whom have placed their trust in the Company for many years," said Hamid Erfanian, CEO of Enzo Biochem.&nbsp; "With the support of our shareholders for the asset sale, we look forward to advancing the Company's "focused return" initiative and maximizing shareholder value in its next phase."

Asset Sales

Enzo Biochem Reports Significant Progress Towards Completing The Clinical Lab Asset Sale; Special Meeting Of Shareholders Indicate That The Asset Sale Proposal Was Approved By The Affirmative Vote Of A Majority Of Enzo's Outstanding Common Stock

<h3>Gainers</h3>
<ul>
<li>PLx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXP#NASDAQ">PLXP</a>) stock moved upwards by 51.2% to $0.16 during Friday's after-market session. PLx Pharma's trading volume hit 2.1 million shares by close, accounting for 558.6% of its average volume over the last 100 days. The company's market cap stands at $4.6 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 41.17% to $1.68. GlucoTrack's trading volume hit 9.0 million shares by close, accounting for 49814.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $26.0 million. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) shares increased by 21.76% to $2.35. Trading volume for this security closed at 746.6K, accounting for 1448.4% of its average full-day volume over the last 100 days. The company's market cap stands at $19.1 million. </li>
<li>Better Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTTX#NASDAQ">BTTX</a>) shares increased by 18.03% to $1.44. Better Therapeutics's trading volume hit 169.8K shares by close, accounting for 508.4% of its average volume over the last 100 days. The market value of their outstanding shares is at $34.3 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) stock increased by 16.16% to $0.85. The market value of their outstanding shares is at $8.9 million. </li>
<li>Eloxx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELOX#NASDAQ">ELOX</a>) shares rose 16.13% to $6.55. Today's trading volume for this security ended up closing at 99.9K shares, which is 87.1 percent of its average volume over the last 100 days. The company's market cap stands at $14.1 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 10.6% to $0.67 during Friday's after-market session. This security traded at a volume of 1.8 million shares come close, making up 3919.8% of its average volume over the last 100 days. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) stock decreased by 8.07% to $1.14. The market value of their outstanding shares is at $1.1 million. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) stock fell 7.02% to $1.06. </li>
<li>OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) stock declined by 6.46% to $0.29. Trading volume for this security closed at 108.2K, accounting for 24.9% of its average full-day volume over the last 100 days. The company's market cap stands at $34.4 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock fell 6.02% to $6.25. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock decreased by 6.0% to $2.35. The company's market cap stands at $116.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLR

CNSP

COCP

CYTH

DRMA

GCTK

PLXP

RXRX

12 Health Care Stocks Moving In Friday's After-Market Session

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

Enzo Biochem GAAP EPS of $0.41

Jackson Peak Capital Q3 2023  Update

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Enzo Biochem (NYSE:<a href="https://investorplace.com/stock-quotes/enz-stock-quote/">ENZ</a>) just reported results for the first quarter of 2024.<ul><li>Enzo Biochem reported earnings per share of -11 cents.</li><li>The company reported revenue of $7.81 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2023/12/enz-stock-earnings-enzo-biochem-for-q1-of-2024/">ENZ Stock Earnings: Enzo Biochem Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ENZ Stock Earnings: Enzo Biochem Reported Results for Q1 2024

Laughing Water Capital Q4 2023 Letter

Enzo Biochem Inc (ENZ) has risen Friday morning, with the stock adding 0.74% in pre-market trading to 1.36. ENZ's short-term technical score of 82 indicates that the stock has traded more bullishly over the last month than 82% of stocks on the market. In the Diagnostics and Research industry, which ranks 111 out of 146 ind

Should You Hold Enzo Biochem Inc (ENZ) Stock Friday Morning?

Enzo Biochem Inc (ENZ) stock is higher by 8.87% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives ENZ stock a score of  21 out of a possible 100. That rank is primarily influenced by a long-term technical score of 22. ENZ's rank also includes a short-term technical score of 42.  ENZ has an Over

Is Enzo Biochem Inc (ENZ) Stock a Bad Value?

Enzo Biochem (ENZ) has shared an announcement. Enzo Biochem, Inc. has rewarded its top executives for the company's performance in the 2023 fiscal ...

Enzo Biochem Executives Receive Raises and Equity Rewards

Enzo Biochem Non-GAAP EPS of $0.00, revenue of $8.55M

Enzo Biochem Inc (ENZ) reported less than expected earnings this afternoon for Q2 2024. Enzo Biochem reported EPS loss of $0.00 per share. Profits rose 0% year-over-year after reporting an EPS loss of $0.23 per share in its year-ago quarter. The positive growth rate signals that the Healthcare company . Revenues were upbea

Enzo Biochem Down 1.19% To $1.25 After Earnings

ATVI

BVHMF

CDMO

HAYW

LESL

LFCR

NVDA